{"id":5866,"date":"2019-04-01T16:49:16","date_gmt":"2019-04-01T09:49:16","guid":{"rendered":"https:\/\/www.vnras.com\/drug\/?p=5866"},"modified":"2019-04-01T16:49:16","modified_gmt":"2019-04-01T09:49:16","slug":"ung-thu-giai-doan-cuoi-da-duoc-chua-khoi-hoan-toan-tai-my","status":"publish","type":"post","link":"https:\/\/vnras.com\/drug\/ung-thu-giai-doan-cuoi-da-duoc-chua-khoi-hoan-toan-tai-my\/","title":{"rendered":"Ung th\u01b0 giai \u0111o\u1ea1n cu\u1ed1i \u0111\u00e3 \u0111\u01b0\u1ee3c ch\u1eefa kh\u1ecfi ho\u00e0n to\u00e0n t\u1ea1i M\u1ef9"},"content":{"rendered":"

B\u1ed1n ng\u00e0y tr\u01b0\u1edbc, ng\u00e0y 18\/10\/2017, Hi\u1ec7p h\u1ed9i th\u1ef1c ph\u1ea9m v\u00e0 thu\u1ed1c c\u1ee7a M\u1ef9- FDA (The U.S. Food and Drug Administration) \u0111\u00e3 c\u1ea5p ph\u00e9p cho Yescarta (t\u00ean th\u01b0\u01a1ng m\u1ea1i c\u1ee7a CAR-T cell therapies) \u0111\u01b0\u1ee3c ph\u00e1t tri\u1ec3n b\u1edfi Gilead Science, nh\u01b0 m\u1ed9t ph\u01b0\u01a1ng ph\u00e1p ch\u1eefa tr\u1ecb \u0111\u1ed1i v\u1edbi m\u1ed9t s\u1ed1 b\u1ec7nh ung th\u01b0<\/strong>.<\/p>\n

Th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng \u0111\u01b0\u1ee3c ti\u1ebfn h\u00e0nh tr\u00ean 101 b\u1ec7nh nh\u00e2n ung th\u01b0 m\u00e1u (lo\u1ea1i non-Hodgkin lymphoma) trong v\u00f2ng 6 th\u00e1ng. \u0110\u00e2y l\u00e0 nh\u1eefng b\u1ec7nh nh\u00e2n giai \u0111o\u1ea1n cu\u1ed1i, ho\u00e0n to\u00e0n h\u1ebft hy v\u1ecdng s\u1ed1ng v\u00ec c\u01a1 th\u1ec3 kh\u00f4ng \u0111\u00e1p \u1ee9ng v\u1edbi h\u00f3a tr\u1ecb v\u00e0 x\u1ea1 tr\u1ecb. Sau qu\u00e1 tr\u00ecnh \u0111i\u1ec1u tr\u1ecb, 36% b\u1ec7nh nh\u00e2n trong s\u1ed1 n\u00e0y \u0111\u01b0\u1ee3c ch\u1ee9ng nh\u1eadn ho\u00e0n to\u00e0n kh\u00f4ng c\u00f3 d\u1ea5u hi\u1ec7u c\u1ee7a t\u1ebf b\u00e0o ung th\u01b0 (theo th\u00f4ng c\u00e1o b\u00e1o ch\u00ed c\u1ee7a FDA, t\u1ef7 l\u1ec7 kh\u1ecfi b\u1ec7nh ho\u00e0n to\u00e0n l\u00e0 51% (1)), v\u00e0 82% b\u1ec7nh nh\u00e2n c\u00f3 kh\u1ed1i u thu nh\u1ecf l\u1ea1i \u00edt nh\u1ea5t m\u1ed9t n\u1eeda so v\u1edbi k\u00edch th\u01b0\u1edbc ban \u0111\u1ea7u.Tuy nhi\u00ean, h\u01a1n 40% ph\u1ea3i ch\u1ed1ng tr\u1ecdi v\u1edbi c\u00e1c t\u00e1c d\u1ee5ng ph\u1ee5 nh\u01b0 h\u1ed9i ch\u1ee9ng gi\u1ea3i ph\u00f3ng cytokine (cytokine release syndrome) v\u1edbi c\u00e1c bi\u1ec3u hi\u1ec7n nh\u01b0 s\u1ed1t cao, \u0111au \u0111\u1ea7u, m\u1ec7t m\u1ecfi, \u0111au nh\u1ee9c\u2026, s\u1ef1 suy gi\u1ea3m b\u1ea1ch c\u1ea7u, v\u00e0 s\u1ef1 hi\u1ec7n di\u1ec7n c\u1ee7a \u0111\u1ed9c t\u1ed1 trong n\u00e3o. Hai b\u1ec7nh nh\u00e2n qua \u0111\u1eddi v\u00ec c\u00e1c bi\u1ebfn ch\u1ee9ng li\u00ean quan \u0111\u1ebfn qu\u00e1 tr\u00ecnh \u0111i\u1ec1u tr\u1ecb (2).<\/p>\n

V\u1edbi t\u1ef7 l\u1ec7 kh\u1ecfi b\u1ec7nh ho\u00e0n to\u00e0n kh\u00e1 cao, Yescarta th\u1ef1c s\u1ef1 l\u00e0 hy v\u1ecdng cho c\u00e1c b\u1ec7nh nh\u00e2n ung th\u01b0 m\u00e1u, \u0111\u1eb7c bi\u1ec7t l\u00e0 nh\u1eefng b\u1ec7nh nh\u00e2n \u0111\u00e3 ho\u00e0n to\u00e0n m\u1ea5t hy v\u1ecdng t\u1eeb c\u00e1c ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb kh\u00e1c. Tuy nhi\u00ean, v\u00ec c\u00e1c t\u00e1c d\u1ee5ng ph\u1ee5 nguy hi\u1ec3m, FDA ch\u1ec9 c\u1ea5p ph\u00e9p \u0111i\u1ec1u tr\u1ecb cho c\u00e1c tr\u01b0\u1eddng h\u1ee3p \u0111\u00e3 th\u1ea5t b\u1ea1i v\u1edbi \u00edt nh\u1ea5t 2 trong 3 li\u1ec7u ph\u00e1p \u0111i\u1ec1u tr\u1ecb ch\u00ednh th\u1ed1ng (bao g\u1ed3m ph\u1eabu thu\u1eadt, h\u00f3a tr\u1ecb, v\u00e0 x\u1ea1 tr\u1ecb). \u0110\u1ed3ng th\u1eddi Gilead Science (c\u00f4ng ty d\u01b0\u1ee3c n\u1eafm gi\u1eef b\u1ea3n quy\u1ec1n c\u1ee7a Yescarta) c\u0169ng \u0111\u01b0\u1ee3c y\u00eau c\u1ea7u theo d\u00f5i ch\u1eb7t ch\u1ebd c\u00e1c b\u1ec7nh nh\u00e2n sau qu\u00e1 tr\u00ecnh \u0111i\u1ec1u tr\u1ecb.<\/p>\n

Yescarta ho\u1ea1t \u0111\u1ed9ng nh\u01b0 th\u1ebf n\u00e0o (3, 4)<\/p>\n

\u0110\u00e2y l\u00e0 ph\u01b0\u01a1ng ph\u00e1p ch\u1eefa tr\u1ecb ung th\u01b0 b\u1eb1ng c\u00e1ch t\u0103ng c\u01b0\u1eddng h\u1ec7 th\u1ed1ng mi\u1ec5n d\u1ecbch c\u1ee7a ng\u01b0\u1eddi b\u1ec7nh (Cancer Immunotherapy). B\u1ec7nh ung th\u01b0 l\u00e0 m\u1ed9t cu\u1ed9c chi\u1ebfn gi\u1eefa c\u00e1c t\u1ebf b\u00e0o ung th\u01b0 v\u00e0 c\u01a1 th\u1ec3 ng\u01b0\u1eddi b\u00eanh. V\u0169 kh\u00ed c\u1ee7a c\u01a1 th\u1ec3 l\u00e0 h\u1ec7 mi\u1ec5n d\u1ecbch v\u1edbi c\u00e1c t\u1ebf b\u00e0o T-cells (m\u1ed9t d\u1ea1ng c\u1ee7a t\u1ebf b\u00e0o b\u1ea1ch c\u1ea7u) c\u00f3 th\u1ec3 ti\u00eau di\u1ec7t t\u1ebf b\u00e0o ung th\u01b0. Tuy nhi\u00ean, c\u00e1c t\u1ebf b\u00e0o ung th\u01b0 l\u1ea1i c\u00f3 kh\u1ea3 n\u0103ng v\u00f4 hi\u1ec7u h\u00f3a c\u00e1c t\u1ebf b\u00e0o T-cells n\u00e0y, v\u00e0 d\u1ea7n d\u1ea7n \u0111\u00e1nh b\u1ea1i h\u1ec7 mi\u1ec5n d\u1ecbch. May m\u1eafn l\u00e0 c\u00e1c t\u1ebf b\u00e0o ung th\u01b0, tuy m\u1ea1nh, v\u1eabn \u0111\u1ec3 l\u1ed9 \u0111i\u1ec3m y\u1ebfu l\u00e0 ti\u1ebft ra c\u00e1c kh\u00e1ng nguy\u00ean \u0111\u1eb7c tr\u01b0ng (tumor specific antigen). C\u00e1c kh\u00e1ng nguy\u00ean n\u00e0y nh\u01b0 nh\u1eefng \u201cc\u00e1i \u0111u\u00f4i ph\u1ea3n ch\u1ee7\u201d, c\u00f3 th\u1ec3 khi\u1ebfn c\u00e1c t\u1ebf b\u00e0o ung th\u01b0 b\u1ecb ph\u00e1t hi\u1ec7n v\u00e0 ti\u00eau di\u1ec7t. Yescarta cung c\u1ea5p cho c\u01a1 th\u1ec3 c\u00e1c t\u1ebf b\u00e0o T cells th\u00f4ng minh v\u00e0 m\u1ea1nh m\u1ebd, c\u00f3 th\u1ec3 ph\u00e1t hi\u1ec7n \u201cc\u00e1i \u0111u\u00f4i\u201d kh\u00e1ng nguy\u00ean c\u1ee7a t\u1ebf b\u00e0o ung th\u01b0 v\u00e0 ti\u00eau di\u1ec7t ch\u00fang. (\u0110\u1ec3 hi\u1ec3u th\u00eam v\u1ec1 ph\u1ea7n n\u00e0y, ng\u01b0\u1eddi \u0111\u1ecdc c\u00f3 th\u1ec3 t\u00ecm hi\u1ec3u tr\u00ean Wikipedia v\u1edbi c\u00e1c t\u1eeb kh\u00f3a b\u1eb1ng ti\u1ebfng anh t\u00e1c gi\u1ea3 \u0111\u00e3 cung c\u1ea5p).<\/p>\n

Ph\u01b0\u01a1ng ph\u00e1p ch\u1eefa tr\u1ecb b\u1eaft \u0111\u1ea7u b\u1eb1ng vi\u1ec7c l\u1ea5y m\u1eabu m\u00e1u c\u1ee7a b\u1ec7nh nh\u00e2n, ph\u00e2n t\u00e1ch t\u1ebf b\u00e0o T-cells v\u00e0 bi\u1ebfn \u0111\u1ed5i gene c\u00e1c t\u1ebf b\u00e0o n\u00e0y (genetic modify). Vi\u1ec7c bi\u1ebfn \u0111\u1ed5i gene gi\u00fap g\u1eafn v\u00e0o tr\u00ean b\u1ec1 m\u1eb7t T-cells c\u00e1c th\u1ee5 th\u1ec3 (hay \u0111\u1ea7u thu nh\u1eadn) (receptor) \u0111\u01b0\u1ee3c g\u1ecdi l\u00e0 Chimeric Antigen Receptors hay CARs. Th\u1ee5 th\u1ec3 n\u00e0y c\u00f3 1 v\u00f9ng b\u00e1m d\u00ednh (target-biding domain) gi\u00fap ph\u00e1t hi\u1ec7n v\u00e0 b\u00e1m v\u00e0o c\u00e1c kh\u00e1ng nguy\u00ean \u0111\u1eb7c tr\u01b0ng, \u201cc\u00e1i \u0111u\u00f4i\u201d c\u1ee7a c\u00e1c t\u1ebf b\u00e0o ung th\u01b0, v\u00e0 m\u1ed9t v\u00f9ng k\u00edch ho\u1ea1t (activation domain) ch\u1ecbu tr\u00e1ch nhi\u1ec7m k\u00edch ho\u1ea1t t\u1ebf b\u00e0o T-cells khi \u0111\u00e3 b\u00e1m v\u00e0o kh\u00e1ng nguy\u00ean. Nh\u1eefng CAR-T cells th\u1ebf h\u1ec7 m\u1edbi c\u00f2n c\u00f3 th\u00eam nh\u1eefng v\u00f9ng \u201c\u0111\u1ed3ng k\u00edch th\u00edch\u201d (costimulation domains) gi\u00fap t\u0103ng c\u01b0\u1eddng ph\u1ea3n \u1ee9ng c\u1ee7a h\u1ec7 mi\u1ec5n d\u1ecbch. C\u00e1c t\u1ebf b\u00e0o T-cells nguy\u00ean b\u1ea3n c\u1ee7a c\u01a1 th\u1ec3 kh\u00f4ng c\u00f3 c\u00e1c th\u1ee5 th\u1ec3 n\u00e0y, v\u00e0 v\u00ec th\u1ebf kh\u00f4ng th\u1ec3 th\u1eafng trong cu\u1ed9c chi\u1ebfn v\u1edbi c\u00e1c t\u1ebf b\u00e0o ung th\u01b0.<\/p>\n

CAR-T cell sau khi \u0111\u01b0\u1ee3c \u201cthi\u1ebft k\u1ebf\u201d xong, s\u1ebd \u0111\u01b0\u1ee3c nu\u00f4i c\u1ea5y trong ph\u00f2ng th\u00ed nghi\u1ec7m \u0111\u1ec3 nh\u00e2n l\u00ean h\u00e0ng tr\u0103m tri\u1ec7u b\u1ea3n. Sau \u0111\u00f3 h\u00e0ng tr\u0103m tri\u1ec7u b\u1ea3n n\u00e0y s\u1ebd \u0111\u01b0\u1ee3c \u0111\u01b0a ng\u01b0\u1ee3c tr\u1edf l\u1ea1i c\u01a1 th\u1ec3 b\u1ec7nh nh\u00e2n.<\/p>\n

\u1ede trong c\u01a1 th\u1ec3 b\u1ec7nh nh\u00e2n, T-cells th\u00f4ng minh ti\u1ebfp t\u1ee5c nh\u00e2n l\u00ean r\u1ea5t nhi\u1ec1u l\u1ea7n. V\u1edbi s\u1ef1 h\u01b0\u1edbng d\u1eabn c\u1ee7a th\u1ee5 th\u1ec3, ch\u00fang s\u1ebd \u0111i t\u00ecm v\u00e0 ti\u00eau di\u1ec7t c\u00e1c t\u1ebf b\u00e0o ung th\u01b0 c\u00f3 \u201cc\u00e1i \u0111u\u00f4i\u201d kh\u00e1ng nguy\u00ean \u0111\u1eb7c hi\u1ec7u. M\u1ed9t s\u1ed1 l\u01b0\u1ee3ng T-cells \u0111\u1ee7 l\u1edbn v\u00e0 \u0111\u1ee7 th\u00f4ng minh s\u1ebd gi\u00fap ti\u00eau di\u1ec7t ho\u00e0n to\u00e0n c\u00e1c t\u1ebf b\u00e0o ung th\u01b0.<\/p>\n

Nh\u01b0\u1ee3c \u0111i\u1ec3m c\u1ee7a CAR-T cells<\/h2>\n

\u0110\u00e2y l\u00e0 m\u1ed9t ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb \u0111\u1ea7y tri\u1ec3n v\u1ecdng, th\u1ec3 hi\u1ec7n \u1edf k\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng. Tuy nhi\u00ean, ph\u01b0\u01a1ng ph\u00e1p n\u00e0y c\u0169ng c\u00f3 m\u1ed9t s\u1ed1 h\u1ea1n ch\u1ebf sau :<\/p>\n

    \n
  1. T\u00ednh \u0111\u1eb7c hi\u1ec7u : V\u00ec ph\u01b0\u01a1ng ph\u00e1p ch\u1eefa b\u1ec7nh d\u1ef1a tr\u00ean vi\u1ec7c thi\u1ebft k\u1ebf c\u00e1c t\u1ebf b\u00e0o T-cells th\u00f4ng minh n\u00ean t\u00ednh \u0111\u1eb7c hi\u1ec7u r\u1ea5t cao. M\u1ed9t th\u1ee5 th\u1ec3 (receptor) nh\u01b0 m\u1ed9t \u1ed5 kh\u00f3a ch\u1ec9 c\u00f3 \u0111\u01b0\u1ee3c m\u1edf b\u1edfi m\u1ed9t chi\u1ebfc ch\u00eca kh\u00f3a l\u00e0 kh\u00e1ng nguy\u00ean. V\u00ec th\u1ebf T-cells th\u00f4ng minh ch\u1ec9 \u0111\u01b0\u1ee3c thi\u1ebft k\u1ebf \u0111\u1ec3 ch\u1eefa kh\u1ecfi m\u1ed9t lo\u1ea1i ung th\u01b0 duy nh\u1ea5t. Yescarta (ph\u01b0\u01a1ng ph\u00e1p \u0111\u01b0\u1ee3c c\u1ea5p ph\u00e9p b\u1edfi FDA) \u0111\u01b0\u1ee3c thi\u1ebft k\u1ebf \u0111\u1ec3 t\u01b0\u01a1ng t\u00e1c v\u1edbi protein CD19, l\u00e0 kh\u00e1ng nguy\u00ean c\u1ee7a m\u1ed9t s\u1ed1 lo\u1ea1i ung th\u01b0 m\u00e1u, v\u00ec v\u1eady, Yescarta ch\u1ec9 c\u00f3 th\u1ec3 ch\u1eefa \u0111\u01b0\u1ee3c b\u1ec7nh ung th\u01b0 m\u00e1u (lo\u1ea1i non-Hodgkin lymphoma). Ngo\u00e0i ra, t\u1ebf b\u00e0o T-cells \u0111\u01b0\u1ee3c l\u1ea5y t\u1eeb c\u01a1 th\u1ec3 ng\u01b0\u1eddi b\u1ec7nh, n\u00ean m\u1ed7i ng\u01b0\u1eddi s\u1ebd c\u1ea7n c\u00f3 m\u1ed9t \u00ab lo\u1ea1i thu\u1ed1c s\u1ed1ng-living drug \u00bb \u0111\u01b0\u1ee3c thi\u1ebft k\u1ebf ri\u00eang. Hay n\u00f3i c\u00e1ch kh\u00e1c, thu\u1ed1c c\u1ee7a ng\u01b0\u1eddi n\u00e0y kh\u00f4ng th\u1ec3 ch\u1eefa b\u1ec7nh cho ng\u01b0\u1eddi kh\u00e1c. T\u00ednh \u0111\u1eb7c hi\u1ec7u n\u00e0y s\u1ebd k\u00e9o theo c\u00e1c nh\u01b0\u1ee3c \u0111i\u1ec3m kh\u00e1c c\u1ee7a ph\u01b0\u01a1ng ph\u00e1p ch\u1eefa tr\u1ecb l\u00e0 th\u1eddi gian v\u00e0 chi ph\u00ed.<\/li>\n
  2. Hi\u1ec7n t\u01b0\u1ee3ng m\u1ea5t kh\u00e1ng nguy\u00ean \u0111\u1eb7c hi\u1ec7u : Nh\u01b0 \u0111\u00e3 n\u00f3i \u1edf tr\u00ean, kh\u00e1ng nguy\u00ean \u0111\u1eb7c hi\u1ec7u (antigen) l\u00e0 \u00ab c\u00e1i \u0111u\u00f4i ph\u1ea3n ch\u1ee7 \u00bb, l\u00e0 \u0111i\u1ec3m y\u1ebfu c\u1ee7a t\u1ebf b\u00e0o ung th\u01b0. R\u1ea5t kh\u00f4ng may l\u00e0 nh\u1eefng kh\u00e1ng nguy\u00ean n\u00e0y c\u00f3 th\u1ec3 m\u1ea5t \u0111i theo th\u1eddi gian, k\u00e9o theo s\u1ef1 m\u1ea5t t\u00e1c d\u1ee5ng c\u1ee7a t\u1ebf b\u00e0o T-cells th\u00f4ng minh.<\/li>\n
  3. Th\u1eddi gian : Th\u1eddi gian \u0111\u1ec3 thi\u1ebft k\u1ebf \u0111\u01b0\u1ee3c T-cells th\u00f4ng minh cho m\u1ed9t ng\u01b0\u1eddi b\u1ec7nh v\u00e0 nu\u00f4i c\u1ea5y trong ph\u00f2ng th\u00ed nghi\u1ec7m \u0111\u1ec3 nh\u00e2n l\u00ean h\u00e0ng tr\u0103m tri\u1ec7u b\u1ea3n c\u00f3 th\u1ec3 m\u1ea5t v\u00e0i tu\u1ea7n. Tuy nhi\u00ean, g\u1ea7n \u0111\u00e2y m\u1ed9t s\u1ed1 ph\u00f2ng th\u00ed nghi\u00eam c\u00f4ng b\u1ed1 h\u1ecd c\u00f3 th\u1ec3 ho\u00e0n th\u00e0nh vi\u1ec7c n\u00e0y trong v\u00e0i ng\u00e0y (3).<\/li>\n
  4. Chi ph\u00ed: \u0110\u00e2y c\u00f3 th\u1ec3 n\u00f3i l\u00e0 nh\u01b0\u1ee3c \u0111i\u1ec3m l\u1edbn nh\u1ea5t c\u1ee7a ph\u01b0\u01a1ng ph\u00e1p ch\u1eefa tr\u1ecb. Chi ph\u00ed cho m\u1ed9t l\u1ea7n ch\u1eefa tr\u1ecb v\u1edbi Yescarta l\u00e0 373.000 USD, t\u01b0\u01a1ng \u0111\u01b0\u01a1ng kho\u1ea3ng 8.5 t\u1ef7 Vi\u1ec7t Nam \u0111\u1ed3ng. Tuy nhi\u00ean, chi ph\u00ed n\u00e0y c\u00f3 th\u1ec3 \u0111\u00e3 bao g\u1ed3m c\u1ea3 chi ph\u00ed cho qu\u00e1 tr\u00ecnh theo d\u00f5i v\u00e0 \u0111i\u1ec1u tr\u1ecb t\u1ea1i b\u1ec7nh vi\u1ec7n sau khi \u00ab s\u1eed d\u1ee5ng thu\u1ed1c \u00bb. Kho\u1ea3n n\u00e0y, \u1edf M\u1ef9, c\u00f3 th\u1ec3 l\u00ean \u0111\u1ebfn v\u00e0i ch\u1ee5c ngh\u00ecn \u0111\u00f4 cho m\u1ed9t ng\u00e0y. N\u1ebfu th\u1ef1c v\u1eady th\u00ec chi ph\u00ed cho vi\u1ec7c thi\u1ebft k\u1ebf T-cells s\u1ebd ch\u1ec9 kho\u1ea3ng v\u00e0i ch\u1ee5c ngh\u00ecn \u0111\u00f4.<\/li>\n<\/ol>\n

    Ng\u01b0\u1eddi vi\u1ebft th\u1eadm ch\u00ed l\u1ea1c quan tin t\u01b0\u1edfng r\u1eb1ng, trong t\u01b0\u01a1ng lai, n\u1ebfu Vi\u1ec7t Nam mua b\u1ea3n quy\u1ec1n v\u00e0 ch\u1ecbu tr\u00e1ch nhi\u1ec7m kh\u00e2u thi\u1ebft k\u1ebf T-cells, ch\u00ed ph\u00ed ch\u1eafc ch\u1eafn s\u1ebd ch\u1ec9 c\u00f2n v\u00e0i ch\u1ee5c tri\u1ec7u. Kho\u1ea3n ti\u1ec1n tuy kh\u00f4ng nh\u1ecf v\u1edbi thu nh\u1eadp trung b\u00ecnh c\u1ee7a ng\u01b0\u1eddi Vi\u1ec7t, nh\u01b0ng c\u00f3 l\u1ebd v\u1eabn th\u1ea5p h\u01a1n r\u1ea5t nhi\u1ec1u so v\u1edbi chi ph\u00ed hi\u1ec7n nay cho m\u1ed9t b\u1ec7nh nh\u00e2n ung th\u01b0 \u1edf Vi\u1ec7t Nam.
    \nNh\u1eefng nh\u01b0\u1ee3c \u0111i\u1ec3m k\u1ec3 tr\u00ean c\u1ee7a Yescarta \u0111\u1ec1u \u0111ang \u0111\u01b0\u1ee3c nghi\u00ean c\u1ee9u kh\u1eafc ph\u1ee5c (tr\u00ecnh b\u00e0y d\u01b0\u1edbi \u0111\u00e2y) v\u00e0 ch\u1eafc ch\u1eafn trong t\u01b0\u01a1ng lai s\u1ebd cho ra \u0111\u1eddi c\u00e1c ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb ti\u00ean ti\u1ebfn, \u00edt \u0111\u1eb7c hi\u1ec7u, v\u00e0 v\u1edbi chi ph\u00ed th\u1ea5p h\u01a1n nhi\u1ec1u.<\/p>\n

    T\u01b0\u01a1ng lai c\u1ee7a CAR-T cells<\/h2>\n

    Nhi\u1ec1u th\u1ebf h\u1ec7 m\u1edbi c\u1ee7a CAR-T-cells \u0111ang \u0111\u01b0\u1ee3c kh\u1ea9n tr\u01b0\u01a1ng nghi\u00ean c\u1ee9u, v\u1edbi nh\u1eefng c\u1ea3i ti\u1ebfn v\u1ec1 t\u00ednh \u0111\u1eb7c hi\u1ec7u, nh\u1edd \u0111\u00f3 gi\u00fap T-cells th\u00f4ng minh \u0111\u1ed1i ph\u00f3 v\u1edbi hi\u1ec7n t\u01b0\u1ee3ng m\u1ea5t kh\u00e1ng nguy\u00ean, gi\u1ea3m th\u1eddi gian thi\u1ebft k\u1ebf, v\u00e0 gi\u1ea3m chi ph\u00ed \u0111i\u1ec1u tr\u1ecb. D\u01b0\u1edbi \u0111\u00e2y l\u00e0 c\u00e1c h\u01b0\u1edbng nghi\u00ean c\u1ee9u \u0111ang \u0111\u01b0\u1ee3c th\u1ef1c hi\u1ec7n (5):<\/p>\n